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PURPOSE. Sjo¨gren syndrome is an autoimmune disorder that occurs almost exclusively in
women and is associated with extensive inflammation in lacrimal tissue, an immune-mediated
destruction and/or dysfunction of glandular epithelial cells, and a significant decrease in
aqueous tear secretion. We discovered that androgens suppress the inflammation in, and
enhance the function of, lacrimal glands in female mouse models (e.g., MRL/MpJ-Tnfrsf6lpr
[MRL/lpr]) of Sjo¨gren syndrome. In contrast, others have reported that androgens induce an
anomalous immunopathology in lacrimal glands of nonobese diabetic/LtJ (NOD) mice. We
tested our hypothesis that these hormone actions reflect unique, strain- and tissue-specific
effects, which involve significant changes in the expression of immune-related glandular
genes.
METHODS. Lacrimal glands were obtained from age-matched, adult, female MRL/lpr and NOD
mice after treatment with vehicle or testosterone for up to 3 weeks. Tissues were processed
for analysis of differentially expressed mRNAs using CodeLink Bioarrays and Affymetrix
GeneChips. Data were analyzed with bioinformatics and statistical software.
RESULTS. Testosterone significantly influenced the expression of numerous immune-related
genes, ontologies, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in
lacrimal glands of MRL/lpr and NOD mice. The nature of this hormone-induced immune
response was dependent upon the autoimmune strain, and was not duplicated within
lacrimal tissues of nonautoimmune BALB/c mice. The majority of immune-response genes
regulated by testosterone were of the inflammatory type.
CONCLUSIONS. Our findings support our hypothesis and indicate a major role for the lacrimal
gland microenvironment in mediating androgen effects on immune gene expression.
Keywords: testosterone, Sjo¨gren syndrome, lacrimal gland, gene expression, MRL/lpr-lpr/lpr
mice, nonobese diabetic mice
One leading cause of aqueous-deficient dry eye disease(ADDE) in humans is Sjo¨gren syndrome (SS).1 This
autoimmune disease occurs almost exclusively in women and
is associated with an extensive inflammation in the lacrimal
gland, immune-mediated destruction and/or dysfunction of
glandular epithelial cells, and significant decrease in aqueous
tear output.1 This sexual dichotomy in SS prevalence has been
linked to the more potent immune capability of women,2–4 as
well as to the differential action of sex steroids on the immune
system.5 Androgens often provide a protective influence and
suppress various immunopathologies in SS and other autoim-
mune diseases. In contrast, estrogens have been implicated in
the pathogenesis and/or progression of numerous autoimmune
disorders, including SS.2,5–7
Of particular interest, androgen deficiency appears to have
an important role in the development of lacrimal gland
inflammation and ADDE in SS. Correction of this hormonal
deficit, in turn, may have a therapeutic benefit. To explain,
androgens are very potent regulators of the lacrimal gland and
their action seems to account for many of the sex-related
differences that exist in the anatomy, biochemistry, physiology,
immunology, and molecular biology of this tissue.5 However,
androgen levels in women with SS are significantly de-
creased.8–10 We hypothesized that this reduction predisposes
to lacrimal gland dysfunction, attenuated tear secretion, and
ADDE. In support of our hypothesis, we discovered that
testosterone administration to female mouse models of SS (e.g.,
MRL/MpJ-Tnfrsf6lpr [MRL/lpr] and NZB/NZW F1) suppresses
inflammation in, and increases the functional activity of,
lacrimal tissue.7,11–15 Similarly, topical and/or systemic andro-
gen treatment appears to completely resolve lacrimal gland
inflammation in dry eye dogs,16,17 and to alleviate dry eye signs
and symptoms and promote tear flow in SS patients.5
The mechanism(s) involved in this androgen-induced
suppression of lacrimal gland autoimmune disease in SS
remains to be clarified. Our evidence indicates that this
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hormone action is a unique, tissue-specific effect, which is
initiated through androgen binding to specific receptors in
lacrimal gland epithelial cells.7 In addition, we hypothesize that
this androgen interaction then elicits the altered expression
and/or activity of immune-related genes in lacrimal tissue,
leading to a decrease in immunopathologic lesions and an
improvement in glandular function.
To begin to test this hypothesis, we examined the nature
and magnitude of testosterone’s influence on immune-related
gene expression in the autoimmune lacrimal tissues of female
MRL/lpr mice after onset of disease. We chose the MRL/lpr
strain because, like in humans, the extent of lacrimal and
salivary gland inflammation in MRL/lpr mice is far greater in
females compared to males,18 and is dramatically reduced in
response to androgen treatment.7,11–14
For comparative purposes, we also analyzed and compared
the androgen impact on immune gene expression in lacrimal
glands of female nonobese diabetic/LtJ (NOD) mice after
onset of disease. These mice, which are an established model
for type-1 insulin-dependent diabetes mellitus,19 have been
used as a model for Sjo¨gren syndrome20–22 and, like in
humans, have far greater inflammation in the salivary glands
of females compared to males.18 However, unlike humans, the
lacrimal glands of male NOD mice have significantly higher
inflammation than those of females.18,23–25 Indeed, orchiec-
tomy of NOD mice attenuates, whereas androgen treatment
of castrated NOD males induces, lymphocyte accumulation in
their lacrimal glands.23 This anomalous hormone effect is
mediated through the lacrimal microenvironment24 and
contrasts with the androgen-induced decrease in inflamma-
tion in salivary and pancreatic tissues in these mice.26,27
Given this background, we hypothesized that androgen
exposure will significantly increase the expression and/or
activity of immune-related genes in the lacrimal glands of
female NOD mice. We also hypothesized that these opposing
actions of androgens in female MRL/lpr and NOD lacrimal
tissues involve regulation of similar immune-related genes,
ontologies, and pathways.
MATERIALS AND METHODS
Animals and Tissue Collections
Adult female MRL/lpr and NOD mice were purchased from the
Jackson Laboratories (Bar Harbor, ME, USA). Animals were
maintained in constant temperature rooms with fixed light/
dark intervals 12 hours in duration. Pellets containing vehicle
(cholesterol, methylcellulose, lactose) or testosterone (T; 10
mg) were implanted subcutaneously in MRL/lpr (17.1–18.1
weeks old) and NOD (21 weeks old) mice. The pellets were
obtained from Innovative Research of America (Sarasota, FL,
USA) and were designed for constant release of placebo (P) or
physiologic amounts of androgen (for a male11–14) for a 3-week
period. After 20 to 21 days of treatment, mice (n¼ 7–18 mice/
condition) were killed by CO2 inhalation and exorbital lacrimal
glands were removed for molecular biological procedures.
Lacrimal tissue samples were prepared by combining glands
from two to six mice/strain/group. Three different sample
preparations were made for each treatment (i.e., 4–12 lacrimal
glands/sample/treatment/strain) and then processed for anal-
ysis of gene expression.
All mouse studies were approved by the institutional animal
care and use committee of the Schepens Eye Research Institute
and adhered to the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Ophthal-
mic and Vision Research.
Molecular Biological Procedures
To determine the effect of T on lacrimal gland gene
expression, total RNA was isolated from lacrimal tissues
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and
purified with RNAqueous spin columns (Ambion, Austin, TX,
USA). Lacrimal gland RNA samples were treated with RNase-
free DNase (Invitrogen), assessed spectrophotometrically at
260 nm to determine concentration, and examined with a
RNA 6000 Nano LabChip and an Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA) to verify RNA
integrity. The RNA samples were kept at 808C until further
processing.
Gene expression was determined via two different proce-
dures. One involved hybridization of lacrimal gland RNA
samples to CodeLink (CL) UniSet Mouse 20K I Bioarrays (n ~
20,000 genes/array; Amersham Biosciences/GE Healthcare,
Piscataway, NJ, USA), according to reported methods.28 cDNA
was generated from RNA (2 lg) with a CL Expression Assay
Reagent Kit (Amersham) and purified with a QIAquick
purification kit (Qiagen, Valencia, CA, USA). Samples were
dried, and cRNA was made with a CL Expression Assay Reagent
Kit (Amersham), recovered with an RNeasy kit (Qiagen), and
quantified with an ultraviolet spectrophotometer. Fragmented,
biotin-labeled cRNA then was incubated and shaken at 300
rpm on a CL Bioarray at 378C for 18 hours. Following this time
interval, the Bioarray was washed, exposed to streptavidin-
Alexa 647, and scanned using ScanArray Express software and
a ScanArray Express HT scanner (Packard BioScience, Meriden,
CT, USA) with the laser set at 635 nm, laser power at 100%, and
photomultiplier tube voltage at 60%. Scanned image files were
evaluated using CL image and data analysis software (Amer-
sham), which gave raw and normalized hybridization signal
intensities for each array spot. The intensities of the
approximately 20,000 spots on the Bioarray image were
normalized to a median of 1. Standardized data, with signal
intensities >0.50, were analyzed with bioinformatic software
(Geospiza, Seattle, WA, USA). This comprehensive software
also produced gene ontology, Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway, and z-score reports. The
ontologies included those related to biological processes,
molecular functions, and cellular components, and were
organized according to the recommended guidelines of the
Gene Ontology Consortium (available in the public domain at
http://www.geneontology.org/GO.doc.html).29
The second method to determine differential gene expres-
sion entailed hybridization of each cRNA (20 lg) sample to a
GeneChip Mouse Genome 430A 2.0 Array (Affymetrix [Affy],
Santa Clara, CA, USA) according to the manufacturer’s
protocol. Reagents for the fragmentation and hybridization
steps originated from a GeneChip HT One-Cycle Target
Labeling and Control Kit, and materials for the washing and
staining steps were from a GeneChip HWS kit (Affy).
Hybridized GeneChips were scanned with an Affy Model 700
Scanner and expression data files were generated from array
images using Affy Microarray Suite 4.0 software. GeneChip data
were normalized by choosing the default scaling in the Affy
GeneChip operating software, which gives a trimmed mean
intensity of 500 for each GeneChip microarray. Standardized
data with a quality value of 1.0 then were evaluated with
Geospiza GeneSifter software.
As we reported recently,30 counts of unique mappings of
probes to gene identifications in the CL and Affy arrays
demonstrated that there were 15,711 and 13,265 unique
genes, respectively, in these arrays. Examination of the
intersection of these lists showed that there was an overlap
of 11,299 genes.
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Gene expression data were evaluated without log transfor-
mation and statistical analyses were conducted with Student’s
t-test (2-tailed, unpaired) using the GeneSifter software. Our
statistical method was not tailored for multiple comparisons.
Genes expressed in the same direction in comparative groups
were identified using GenBank accession numbers and a
Geospiza intersector program. Data used for these CL and Affy
arrays are accessible for free download through the National
Center for Biotechnology Information’s Gene Expression
Omnibus (NCBI GEO) via series accession number GSE5877.
We also compared our results to data from our studies
examining the influence of sex in adult MRL/lpr and NOD mice
(n ¼ 15–18/sex/strain),30 and 2 weeks of P or T treatment of
nonautoimmune, ovariectomized BALB/c mice (n¼ 5–6 mice/
condition/experiment),31 on lacrimal gland gene expression.
The sex- and hormone-related data are available through the
NCBI GEO via series accession numbers GSE5876 and
GSE3995, respectively.
TABLE 1. Effect of T on Gene Expression in Lacrimal Glands of Female
MRL/lpr and NOD Mice
Mouse Strain/Array Genes  Genes  Total Genes
MRL/lpr
CL 1890 1708 3598
Affy 1120 1530 2650
NOD
CL 1474 2275 3749
Affy 1102 1150 2252
Data were evaluated without log transformation. The expression of
listed genes was significantly (P < 0.05) up ()- or down ()-regulated
by T treatment.
TABLE 2. T Influence on Gene Expression in Lacrimal Glands of Female MRL/lpr Mice
Accession # Gene Ratio P Value Ontology
T>P, CL
NM_145548 Cytochrome P450, family 2, subfamily j,
polypeptide 13
528.0 0.0000 Oxidation-reduction process
NM_010643 Kallikrein 1-related peptidase b24 273.1 0.0000 Proteolysis
NM_001042711.2 Amylase 2, pancreatic 204.6 0.0087 Endohydrolysis
NM_146592 Olfactory receptor 1086 151.5 0.0062 Signal transduction
NM_020277 Transient receptor potential cation channel,
subfamily M, member 5
142.2 0.0087 Transport
NM_146805 Olfactory receptor 907 121.9 0.0074 Signal transduction
BB149074 Oxysterol binding protein-like 3 111.5 0.0004 Transport
NM_016672 Dopa decarboxylase 109.6 0.0154 Cellular amino acid metabolic process
T>P, Affy
NM_020268 Kallikrein 1-related peptidase b27 2894.0 0.0008 Proteolysis
NM_019515 Neuromedin U 656.7 0.0006 Energy homeostasis
NM_017390 Seminal vesicle secretory protein 2 328.6 0.0190 Fertilization
BC016446 Cytochrome P450, family 2, subfamily j,
polypeptide 13
310.0 0.0018 Oxidation-reduction process
AK020349 Seminal vesicle secretory protein IV 284.2 0.0002 Fertilization
NM_010643 Kallikrein 1-related peptidase b24 268.0 0.0000 Proteolysis
M16360 Major urinary protein V 222.1 0.0011 Transport
AY079153 Melanocortin 2 receptor accessory protein 150.2 0.0001 Positive regulation of camp biosynthetic process
P>T, CL
NM_018874 Pancreatic lipase related protein 1 21.0 0.0049 Lipid metabolic process
NM_024427 Tropomyosin 1, a 18.8 0.0017 In utero embryonic development
NM_011105 Polycystin and REJ 15.8 0.0003 Transport
NM_009714 Asialoglycoprotein receptor 1 11.4 0.0024 Endocytosis
AK002477 Plasma membrane proteolipid 10.6 0.0009 Transport
NM_026123 Unc-50 homolog 9.5 0.0002 Protein transport
BC018468 Endoplasmic reticulum lectin 1 9.0 0.0053 ER-associated protein catabolic process
AW492955 doublecortin domain containing 2a 8.0 0.0015 Neuron migration
P>T, Affy
NM_018874 Pancreatic lipase related protein 1 30.1 0.0008 Lipid metabolic process
M30697 ATP-binding cassette, sub-family B, member 1A 28.2 0.0005 ATP catabolic process
BC005555 Prolactin receptor 22.1 0.0009 Activation of transmembrane receptor protein
tyrosine kinase activity
NM_008109 Growth differentiation factor 5 15.6 0.0004 Cell-cell signaling
U09362 Asialoglycoprotein receptor 1 13.0 0.0012 Endocytosis
NM_013669 Synaptosomal-associated protein 91 12.9 0.0036 Establishment or maintenance of cell polarity
AF147785 Lost on transformation protein 1 11.6 0.0043 Regulation of gene expression
BC024580 Carboxymethylenebutenolidase-like 7.5 0.0078 Hydrolase activity
Accession numbers are the sequence identities of gene fragments expressed on the CL and Affy microarrays. These sequences appear in the
nucleotide database of the NCBI. Relative ratios were determined by comparing the degree of gene expression in lacrimal glands from P- and T-
treated female MRL/lpr mice. Ratios were calculated from nontransformed data.
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RESULTS
T Influence on Gene Expression in Lacrimal
Glands of Female MRL/lpr and NOD Mice
To determine the effect of androgen treatment on gene
expression in lacrimal glands of autoimmune mice, tissues
were obtained from female MRL/lpr and NOD mice (n¼ 7–18
mice/strain/treatment) following 20 to 21 days of exposure to
P or T. Glands were pooled according to treatment and strain
(n ¼ 4–12 glands/samples/strain/treatment; n ¼ 3 samples/
treatment group), processed for isolation of total RNA, and
analyzed for differentially expressed mRNAs using CL Bioarrays
and Affy GeneChips. Microarray data were evaluated with
Geospiza bioinformatics software.
Our results with CL and Affy microarrays showed that
testosterone treatment has a significant influence on expres-
sion of thousands of genes in lacrimal glands of MRL/lpr and
NOD mice (Table 1). Androgen exposure increased () the
activity of genes, such as cytochrome P450, family 2, subfamily
j, polypeptide 13 (Cyt), and decreased () that of pancreatic
lipase–related protein 1 (PL) in both strains (Tables 2, 3). These
two genes also are regulated in the same manner in lacrimal
tissues of nonautoimmune female BALB/c mice (Cyt¼ 9.9-fold
; PL¼ 81.1-fold ; NCBI GEO GSE3995).31
Examples of other genes upregulated in lacrimal glands of
MRL/lpr mice, such as oxysterol binding protein-like 3,
olfactory receptor 1086, and dopa decarboxylase (Table 2),
also were very highly upregulated by 39.4-, 36.8-, and 58.6-fold
amounts, respectively, in NOD lacrimal tissues. In contrast, the
gene expression for cathepsin S, which is significantly elevated
in the tears of Sjo¨gren syndrome patients,32 was significantly (P
< 0.05) decreased by testosterone in female MRL/lpr lacrimal
glands (CL ¼ 1.53-fold ; Affy ¼ 1.88-fold ), but increased by
androgen treatment in those of female NOD mice (CL ¼ 3.87-
TABLE 3. T Impact on Gene Expression in Lacrimal Glands of Female NOD Mice
Accession # Gene Ratio P Value Ontology
T>P, CL
NM_010639 Kallikrein 1 216.7 0.0237 Proteolysis
NM_145548 Cytochrome P450, family 2, subfamily j,
polypeptide 13
212.2 0.0162 Oxidation-reduction process
NM_010643 Kallikrein 1-related peptidase b24 91.1 0.0221 Proteolysis
NM_010644 Kallikrein 1-related peptidase b26 72.9 0.0237 Proteolysis
BC002033 RAD50 homolog 52.0 0.0050 DNA recombination
NM_008957 Patched homolog 1 48.5 0.0071 Signal transduction
BC012259 Major urinary protein 2 47.9 0.0026 Pheromone binding
AK004371 RAS-like, family 11, member A 42.5 0.0007 GTP catabolic process
T>P, Affy
BC016446 Cytochrome P450, family 2, subfamily j,
polypeptide 13
618.5 0.0125 Oxidation-reduction process
U82380 Submaxillary gland androgen regulated protein
2
361.9 0.0003 Response to toxin
NM_010644 Kallikrein 1-related peptidase b26 247.1 0.0145 Proteolysis
BC026378 Kallikrein 1-related peptidase b1 207.3 0.0004 Proteolysis
NM_133997 Apolipoprotein F 154.3 0.0035 Lipid metabolic process
BC009165 Thyroid hormone responsive SPOT14 homolog 95.6 0.0001 Transcription, DNA-dependent
AB065134 Monooxygenase, DBH-like 2 90.4 0.0114 Catecholamine metabolic process
AY079153 Melanocortin 2 receptor accessory protein 84.2 0.0060 Positive regulation of camp biosynthetic process
P>T, CL
NM_018874 Pancreatic lipase related protein 1 1877.1 0.0475 Lipid metabolic process
NM_011105 Polycystin and REJ 38.3 0.0001 Transport
AK002477 Plasma membrane proteolipid 33.6 0.0005 Transport
NM_011857 Teneurin-3 31.1 0.0002 Signal transduction
NM_010726 Phytanoyl-CoA hydroxylase 24.7 0.0001 Fatty acid a-oxidation
NM_026754 Unique cartilage matrix-associated protein 24.4 0.0197 Negative regulation of osteoblast differentiation
NM_019752 HtrA serine peptidase 2 24.4 0.0009 Proteolysis
NM_146242 Leucine rich repeat containing 10 24.3 0.0001 Transport
P>T, Affy
NM_018874 Pancreatic lipase related protein 1 1462.8 0.0059 Lipid metabolic process
AF147785 Lost on transformation protein 1 33.2 0.0002 Regulation of gene expression
BC005555 Prolactin receptor 23.4 0.0095 Activation of transmembrane receptor protein
tyrosine kinase activity
NM_010726 Phytanoyl-CoA hydroxylase 21.8 0.0096 Fatty acid a-oxidation
AK014353 KH domain containing, RNA binding, signal
transduction associated 3
13.5 0.0000 Transcription, DNA-dependent
BC011209 Major facilitator superfamily domain containing
7C
13.5 0.0019 Transport
AY061807 Calmodulin-like 4 13.1 0.0002 Calcium ion binding
NM_134094 Neurocalcin delta 13.0 0.0009 Calcium-mediated signaling
Genes with known ontologies are listed. Relative ratios were calculated by comparing the degree of gene expression in lacrimal glands from P-
and T-treated female NOD mice. Ratios were generated from nontransformed data.
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fold ; Affy ¼ 3.23-fold ). A similar pattern was found for
moesin gene expression, which was reduced by T in female
MRL/lpr lacrimal glands (Affy ¼ 3.19-fold ), but increased by
androgen exposure in lacrimal tissues of female NOD mice
(Affy ¼ 3.39-fold ). Other genes were regulated by T in the
lacrimal tissue of only one strain (e.g., NOD, spleen tyrosine
kinase [Syk]; CL ¼ 3.1-fold ).
As we30,33–35 and other investigators36–39 have discovered,
the vast majority of lacrimal gland genes in MRL/lpr and NOD
female mice, which were identified as differentially expressed
by the CL and Affy microarrays, were unique to each platform.
Indeed, as demonstrated in Table 4, only 8.5% to 11.1% (T>P),
and 7.3% to 16.8% (P>T) of the regulated genes were found by
both microarrays. These data showed that there are significant
differences in the ability of these platforms to detect
differential gene expression.
This low concordance in gene identification appears to be
due to intrinsic variations in multiple aspects of platform
design, as well as to the inherent instability of lists of
significantly changed genes based upon P value cutoffs.36–40
The result is that CL and Affy microarrays, both of which have
documented accuracy and reproducibility, seem to measure
different things.38 Most gene expression differences revealed
by each platform are thought to be biologically correct, and
these variations cannot be attributed to technological differ-
ences.37,38
Comparison of gene expression between the lacrimal
glands of P-treated MRL/lpr and NOD mice demonstrated that
587 genes were in common (CL). The alternate comparison
(i.e., MRL/lpr, T>P; NOD, T>P) revealed 559 genes in common
(CL).
T Effect on Immune-Related Ontologies in
Lacrimal Glands of Female MRL/lpr, NOD and
BALB/c Mice
T exerted a significant influence on the expression of a large
number of immune-related gene ontologies in the lacrimal
glands of female MRL/lpr and NOD mice. Many of these
hormone responses were identified by CL and Affy platforms
(Tables 5, 6).
As demonstrated in Table 5, androgen administration
downregulated the expression of over 60 immune-associated
biological process ontologies (‡20 genes/ontology) in lacrimal
tissues of female MRL/lpr mice, including those related to
immune system processes, lymphocyte activation, cytokine
production, and inflammatory response. In contrast, T
increased the expression of all of these same immune
ontologies, as well as more, in lacrimal glands of female NOD
mice (Table 6). These changes were accompanied by down-
and upregulation of immune-related molecular function (e.g.,
chemokine activity) and cellular component (e.g., MHC
protein complex) ontologies (‡5 genes/ontology) in lacrimal
tissues of MRL/lpr and NOD mice, respectively.
Some genes represented within these immune ontologies
were the same (e.g., MRL/lpr  and NOD : chemokine [C-X-C
motif] ligand 9 [Cxcl9], IL-1b, and toll-like receptors 1 and 2
[TLR 1 and 2]), but most were not. For example, T decreased
the expression of 96 immune-response genes (CL) in lacrimal
glands of MRL/lpr mice (Table 7), but the majority of these
genes were different than the 133 genes (CL) upregulated in
NOD mouse tissues (Table 8). Despite these differences, the
androgen-regulated immune-response genes were predomi-
nantly inflammatory in nature. Thus, T downregulated the
expression of 41 inflammatory genes in MRL/lpr lacrimal
tissues and 23 of these were the same as in Table 7. Further,
androgen administration increased the expression of 52
inflammatory genes in NOD lacrimal glands and 36 of these
were identical to those in Table 8.
Not all immune-related responses to T in the lacrimal glands
of female MRL/lpr and NOD mice were opposite. As shown in
Table 9, the expression of certain inflammatory genes was
down- or upregulated in the same way in both strains.
The modulatory effect of T on immune-related gene
expression in the autoimmune mouse lacrimal glands did not
reflect an androgen action typically found in lacrimal tissues of
a nonautoimmune strain. Indeed, the effect of T on gene
ontologies in lacrimal glands of female NOD, compared to
female BALB/c, mice showed significant differences. For
example, 21 of 22 androgen upregulated biological process
ontologies (Affy) in NOD mice (n ¼ 479 NOD > BALB/c
ontologies) with the highest z-scores (z ¼ 6.85 – 10.59) were
all immune-related. In contrast, only two of the 161 biological
process gene ontologies expressed to a greater extent in BALB/
c versus NOD mice were immune-associated. Instead, the
BALB/c biological process ontologies with the highest z-scores
were translation elongation (z ¼ 11.59), translation (z ¼ 9.56)
and oxidation-reduction (z ¼ 6.87). In the same way, some of
the top molecular function and cellular component ontologies
in T-treated female NOD mice were immune-related antigen
binding (z¼ 8.72), chemokine receptor binding (z¼ 4.63), and
MHC protein complex (z¼6.64), whereas they were structural
constituent of ribosome (z¼10.94), mitochondrion (z¼12.77)
and multiple ontologies related to oxidoreductase activities in
androgen-treated female BALB/c mice.
TABLE 4. Comparative Gene Expression Between CL and Affy Micro-
arrays
Genes
T>P
Genes
P>T
Total
Genes
MRL/lpr
CL
Unique CL genes, not
expressed by Affy
1724 1284 3008
Affy
Unique Affy genes, not
expressed by CL
943 1490 2433
CL vs. Affy
Genes changed in
same direction
143 216 359
Genes changed in
opposite direction
16
NOD
CL
Unique CL genes, not
expressed by Affy
1326 2091 3417
Affy
Unique Affy genes, not
expressed by CL
932 973 1905
CL vs. Affy
Genes changed in
same direction
147 152 299
Genes changed in
opposite direction
13
Data were evaluated without log transformation. Genes identified as
‘‘unique’’ were significantly (P < 0.05) increased on one, but not the
other, microarray platform. The phrase ‘‘Genes changed in the same (or
opposite) direction’’ means that the results were significant (P < 0.05)
on both platforms.
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TABLE 5. T Downregulation of Immune-Related Gene Ontologies in Lacrimal Glands of Female MRL/lpr Mice
Ontology CL Genes  Affy Genes  CL z-score Affy z-score
Biological process
Immune system process 166 130 7.27 3.97
Immune response 90 67 5.45 2.65
Defense response 89 4.73
Regulation of immune system process 79 68 3.9 2.72
Leukocyte activation 65 54 4.58 3.06
Immune system development 61 2.98
Hemopoietic or lymphoid organ development 58 3.02
Lymphocyte activation 55 44 4.11 2.4
Positive regulation of immune system process 55 47 3.33 2.12
Response to cytokine stimulus 47 35 6.4 3.76
Innate immune response 46 35 4.75 2.82
Induction of apoptosis 45 2.82
Regulation of immune response 43 2.31
Cytokine production 41 3.03
Regulation of defense response 41 3.6
Immune effector process 39 2.56
Inflammatory response 39 2.51
Leukocyte differentiation 38 3.13
T cell activation 38 3.46
Positive regulation of immune response 37 2.82
Positive regulation of intracellular protein kinase cascade 36 2.84
Regulation of leukocyte activation 34 34 2.87 3.2
Regulation of cytokine production 33 2.23
Regulation of lymphocyte activation 32 30 3.13 2.92
Cellular response to cytokine stimulus 31 25 4.45 2.98
Leukocyte proliferation 31 23 4.19 2.22
Activation of immune response 30 24 2.98 2.03
Lymphocyte proliferation 30 22 4.08 2.08
Positive regulation of defense response 29 3.61
I-jb kinase/NF-jb cascade 25 3.54
Positive regulation of leukocyte activation 25 24 3.23 2.96
Positive regulation of lymphocyte activation 24 22 3.42 2.77
Regulation of T-cell activation 24 21 2.91 2.44
Cytokine-mediated signaling pathway 23 2.99
Immune response-activating signal transduction 23 20 2.24 2.03
Immune response-regulating signaling pathway 23 2.13
Regulation of leukocyte proliferation 23 20 3.44 2.69
Positive regulation of cytokine production 22 3.22
Regulation of lymphocyte proliferation 22 3.27
B-cell activation 21 2.16
Regulation of innate immune response 21 2.24
T-cell differentiation 20 2.22
T-cell proliferation 20 3.26
Activation of innate immune response 18 2.79
Cytokine biosynthetic process 15 2.35
Cytokine metabolic process 15 2.35
Innate immune response-activating signal transduction 17 2.55
Leukocyte migration 17 2.04
Myeloid leukocyte activation 14 2.25
Myeloid leukocyte differentiation 16 2.4
Positive regulation of I-jb kinase/NF-jb cascade 18 3.38
Positive regulation of innate immune response 19 2.29
Positive regulation of leukocyte proliferation 18 3.56
Positive regulation of lymphocyte proliferation 17 3.37
Positive regulation of mononuclear cell proliferation 17 3.31
Positive regulation of T-cell activation 18 18 3.21 3.29
Regulation of I-jb kinase/NF-jb cascade 19 3.18
Regulation of inflammatory response 17 2.08
Regulation of innate immune response 19 2.06
Regulation of lymphocyte proliferation 19 2.5
Regulation of T-cell proliferation 15 2.73
Toll-like receptor signaling pathway 15 2.15
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T Impact on Immune-Related KEGG Pathways in
Lacrimal Glands of Female MRL/lpr and NOD Mice
T administration led to a significant decrease in the expression
of immune-related KEGG pathways in lacrimal glands of female
MRL/lpr mice (Table 10). These included such pathways as
chemokine signaling, cytokine-cytokine receptor interaction,
and leukocyte transendothelial migration (Table 9). In contrast,
T induced a significant increase in the expression of these
KEGG pathways, as well as many more, in lacrimal tissues of
female NOD mice (Table 11).
Comparison Between the Influence of Sex and T
on Immune-Related Gene Expression in Lacrimal
Glands of MRL/lpr and NOD Mice
Lacrimal glands of female MRL/lpr and male NOD mice,
compared to their opposite sexes, contain a significantly
greater expression of genes, ontologies, and KEGG pathways
related to inflammatory responses, antigen processing, and
chemokine signaling.30 We hypothesized that many of these
immune-related genes, ontologies, and pathways are analogous
to those T suppresses in female MRL/lpr, and induces in female
NOD mouse lacrimal tissues. To test this hypothesis, we
compared the sex and T influence on immune-related gene
expression in MRL/lpr and NOD mice. We also compared these
findings to genes more highly expressed in inflamed (MRL/lpr
female and NOD male) versus noninflamed (MRL/lpr male and
NOD female) lacrimal tissues.
As shown in Tables 12 to 14, many immune-related
biological process ontologies (e.g., inflammatory response),
immune response genes (e.g., complement component 3) and
chemokine KEGG pathway genes (e.g., chemokine [C-X-C
motif] ligand 9) that are influenced by sex and T in lacrimal
glands of MRL/lpr and NOD mice are identical. Thus, androgen
downregulates multiple immune-related genes that are highly
expressed in lacrimal tissues of female MRL/lpr mice, and T
upregulates the expression of these immune genes, which
typically are expressed in NOD males, in female NOD lacrimal
tissues. These regulated genes in Tables 12 to 14 are the same
as those more highly expressed in inflamed compared to
noninflamed lacrimal glands.
DISCUSSION
Our results showed that T significantly influences the
expression of numerous immune-related genes, ontologies,
and KEGG pathways in lacrimal glands of MRL/lpr and NOD
mice. These genes are associated with processes, such as
lymphocyte activation, leukocyte transendothelial migration,
antigen binding, chemokine signaling, cytokine production,
cytokine-cytokine receptor interaction, MHC protein complex,
and the inflammatory response. The nature of this androgen-
induced response depends upon the autoimmune strain and is
not duplicated within lacrimal tissues of nonautoimmune
BALB/c mice. The majority of immune-related genes regulated
by T are of the inflammatory type. Our findings indicated the
lacrimal gland microenvironment as a key mediator of
androgen effects on immune gene expression and the
associated immunopathology.
Our study was prompted by our earlier discovery that
androgens, but not estrogens, dramatically suppress the
inflammation in lacrimal tissues of the female MRL/lpr and
NZB/NZW FI mouse models of SS.11–14 We hypothesized that
this androgen effect involves an alteration in the expression
and/or activity of immune-related genes, because such genes
are critically important in innate and adaptive immune
responses.42 These genes might also have a major role in
promoting the multiple immunosuppressive actions of andro-
gens, including those directly on T cells, monocytes, macro-
phages, neutrophils, and B cell precursors, and indirectly on
peripheral B cells.43,44 These androgen actions lead to
regulation of the maturation, proliferation, migration, and/or
function of immune cells; synthesis and secretion of antibod-
ies, cytokines, adhesion molecules, and proto-oncogenes; and
expression of autoantigens.2,43,44 A result is that androgens are
protective in SS, as well as in other autoimmune diseases, such
as systemic lupus erythematosus, multiple sclerosis, and
rheumatoid arthritis.2,5,6,43
We discovered that testosterone suppresses a wide array of
immune-related genes in lacrimal glands of female MRL/lpr
mice. The question is whether some of these genes may be
intricately involved in helping to mediate testosterone’s anti-
inflammatory action in this tissue. Possible examples abound.
For example, the androgen downregulation of complement 3,
Cxcl9, moesin, IL-1b, and TLR2 genes may interfere with the
early stages of SS disease development and the triggering of an
adaptive immune response in the lacrimal gland.30,45–50
However, if these five genes are important for the androgen-
induced downregulation of lacrimal gland inflammation in
female MRL/lpr mice, why are these same genes upregulated
by androgen treatment in lacrimal tissues of female NOD mice?
Indeed, we found that many of the immune response genes,
immune-related biological process ontologies, and chemokine
KEGG pathway genes that are influenced by sex and T in
TABLE 5. Continued
Ontology CL Genes  Affy Genes  CL z-score Affy z-score
Molecular function
Cytokine binding 16 2.22
Cytokine receptor activity 10 2.35
Chemokine receptor binding 9 10.00 2.57 3.23
Antigen binding 8.00 5.16
Chemokine activity 7 2.11
NF-jb binding 5 2
Cellular components
MHC protein complex 5 2.38
Biological process (‡20 genes/ontology), molecular function (‡5 genes/ontology) and cellular component (‡5 genes/ontology) immune
ontologies were identified after the analysis of nontransformed CL and Affy data. These immune ontologies were upregulated in lacrimal gland
samples from P-treated female mice, and by extension, downregulated in lacrimal gland tissues from androgen-treated mice. A z-score is a statistical
rating of the relative expression of genes, and shows how greatly they are over- or underrepresented in a specific gene list.41 Positive z-scores
represent a higher number of genes meeting the criterion than is anticipated by chance, and values >2.0 are significant. CL Genes , number of
genes downregulated, as calculated with a CL Bioarray; Affy Genes , number of genes downregulated, as determined with Affy GeneChips; z-score,
specific score for the down-regulated genes in the CL- and Affy-related tissues.
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TABLE 6. T Upregulation of Immune-Related Gene Ontologies in Lacrimal Glands of Female NOD Mice
Ontology CL Genes  Affy Genes  CL z-Score Affy z-Score
Biological process
Immune system process 192 137 13.29 9.08
Immune response 127 85 13.54 8.8
Defense response 115 80 10.91 7.13
Regulation of immune system process 111 77 11.05 7.28
Leukocyte activation 87 61 10.52 7.15
Positive regulation of immune system process 86 65 10.98 8.35
Regulation of immune response 77 50 10.88 6.86
Lymphocyte activation 72 53 9.2 6.77
Immune effector process 71 46 11.16 7.07
Immune system development 69 50 6.12 4.13
Innate immune response 62 44 10.06 7.31
Positive regulation of immune response 62 44 10.1 7.34
Cytokine production 59 37 8.52 4.88
Regulation of leukocyte activation 54 37 9.16 6.14
T-cell activation 53 40 8.5 6.65
Inflammatory response 51 30 6.57 2.85
Regulation of cytokine production 51 33 7.85 4.74
Leukocyte differentiation 49 35 7.11 4.95
Regulation of defense response 49 33 6.9 4.27
Regulation of lymphocyte activation 48 34 8.63 6.06
Leukocyte mediated immunity 47 28 9.82 5.53
Activation of immune response 44 34 8.01 6.84
Positive regulation of leukocyte activation 43 30 9.99 6.75
Regulation of immune effector process 43 21 9.15 3.79
Lymphocyte mediated immunity 40 26 9.36 6.05
Positive regulation of lymphocyte activation 40 27 9.75 6.21
Chemotaxis 39 29 3.94 2.61
Response to cytokine stimulus 39 30 5.89 4.52
Adaptive immune response 38 28 8.19 6.22
Adaptive immune response based on somatic recombination of
immune receptors built from immunoglobulin
38 28 8.36 6.46
Immune response-regulating signaling pathway 38 29 7.65 6.61
Leukocyte proliferation 38 27 7.5 5.21
Lymphocyte differentiation 38 27 6.89 4.73
Immune response-activating signal transduction 37 29 7.51 6.7
Lymphocyte proliferation 37 27 7.41 5.37
Regulation of T-cell activation 35 26 7.42 5.81
Positive regulation of defense response 32 25 5.68 4.8
Regulation of leukocyte proliferation 32 21 7.54 4.68
B-cell activation 31 25 6.32 5.38
Positive regulation of cytokine production 31 7.33
Regulation of innate immune response 31 21 6.42 4.33
Regulation of lymphocyte proliferation 31 21 7.39 4.82
Positive regulation of immune effector process 30 9.08
Positive regulation of T-cell activation 30 22 8.82 6.53
Regulation of leukocyte mediated immunity 30 8.99
T-cell differentiation 30 6.47
Negative regulation of immune system process 28 18 5.77 3.55
Cellular response to cytokine stimulus 26 23 4.19 4.15
Positive regulation of leukocyte proliferation 26 15 7.74 3.88
Regulation of adaptive immune response 26 7.9
Regulation of adaptive immune response based on somatic
recombination of immune receptors built from
26 7.99
T-cell proliferation 26 16 6.44 3.65
Myeloid leukocyte activation 25 7.58
Positive regulation of innate immune response 25 18 5.28 4.02
Positive regulation of lymphocyte proliferation 25 15 7.58 4.04
Regulation of lymphocyte mediated immunity 25 7.93
Regulation of lymphocyte differentiation 24 7.77
B-cell mediated immunity 23 7.08
Immune response-regulating cell surface receptor signaling
pathway
23 8.11
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TABLE 6. Continued
Ontology CL Genes  Affy Genes  CL z-Score Affy z-Score
Antigen processing and presentation 22 20 9.6 9.59
I-jb kinase/NF-jb cascade 22 22 3.68 4.77
Immune response-activating cell surface receptor signaling
pathway
22 7.86
Immunoglobulin mediated immune response 22 6.74
Regulation of B-cell activation 22 7
Cell activation involved in immune response 21 5.39
Cytokine biosynthetic process 21 5.59
Cytokine metabolic process 21 5.59
Cytokine-mediated signaling pathway 21 16 3.4 2.5
Leukocyte activation involved in immune response 21 5.39
Positive regulation of adaptive immune response 21 8.66
Positive regulation of adaptive immune response based on somatic
recombination of immune receptors b
21 8.66
Leukocyte migration 20 4
Positive regulation of leukocyte mediated immunity 20 8.4
Positive regulation of lymphocyte mediated immunity 20 8.4
Regulation of T-cell proliferation 20 5.67
Activation of innate immune response 19 17 4.1 4.51
Leukocyte mediated cytotoxicity 19 7.39
Positive regulation of lymphocyte differentiation 19 8.42
Innate immune response-activating signal transduction 18 17 3.83 4.62
Positive regulation of B-cell activation 18 7.35
Regulation of T-cell differentiation 18 6.28
a-b T-cell activation 17 5.05
Positive regulation of I-jb kinase/NF-jb cascade 17 13 3.94 3.27
Positive regulation of T-cell proliferation 17 6.39
Regulation of I-jb kinase/NF-jb cascade 17 16 3.41 3.99
Regulation of inflammatory response 17 2.98
T-cell differentiation in thymus 17 6.18
B-cell differentiation 16 5.5
Leukocyte chemotaxis 16 4.47
Myeloid leukocyte differentiation 16 3.28
Positive regulation of T-cell differentiation 16 7.45
Toll-like receptor signaling pathway 16 3.38
Negative regulation of cytokine production 14 3.93
Molecular function
Cytokine activity 29 4.88
Cytokine receptor binding 24 3.36
Cytokine binding 20 4.68
Chemokine receptor binding 11 8 4.46 3.21
Chemokine activity 10 6 4.66 2.59
Antigen binding 9 10 6.9 8.35
Cytokine receptor activity 8 2.06
Chemokine binding 6 3.33
Chemokine receptor activity 6 3.64
C-C chemokine binding 5 3.48
C-C chemokine receptor activity 5 3.68
MHC protein binding 5 5.31
CCR chemokine receptor binding 4 3.6
Chemoattractant activity 4 2.9
MHC class I protein binding 4 4.75
Cellular components
MHC protein complex 11 11 7.99 8.96
T cell receptor complex 7 8
MHC class II protein complex 6 6 6.24 6.98
a-b T-cell receptor complex 5 7.32
CD40 receptor complex 5 5.3
Immunological synapse 5 4.11
Biological process (‡20 genes/ontology), molecular function (‡5 genes/ontology) and cellular component (‡5 genes/ontology) immune
ontologies were identified after the evaluation of nontransformed CL and Affy data. CL Genes , number of genes up-regulated, as identified with a
CL Bioarray; Affy Genes , number of genes up-regulated, as found with Affy GeneChips; z-score, specific score for the up-regulated genes in the CL
and Affy related tissues.
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TABLE 7. T-Induced Decrease of Gene Expression in the Immune Response Ontology in Lacrimal Glands From Female MRL/lpr Mice
Gene CL Ratio Affy Ratio CL P Value Affy P Value
Indoleamine 2,3-dioxygenase 1 4.55 0.0073
Guanylate binding protein 2* 4.31 2.63 0.0016 0.0004
Linker for activation of T cells family, member 2* 4.09 0.0024
Ectonucleotide pyrophosphatase/phosphodiesterase 3.61 0.0033
Synaptic cell adhesion molecule 1 3.52 0.0009
Chemokine (C-X-C motif) ligand 11 3.12 0.0185
Properdin 3.4 0.0242
Chemokine (C-X-C motif) ligand 16 3.01 2.08 0.0003 0.0377
Histocompatibility 2, class II antigen A, b1 2.98 0.0037
Complement component 3 2.94 2.53 0.0015 0.0052
C-type lectin domain family 2, member d 2.9 1.9 0.0007 0.0407
Toll-like receptor 4, mRNA 2.89 0.0094
Interleukin 1 receptor accessory protein, transcript variant 2 2.81 0.0021
Protein tyrosine phosphatase, receptor type, C, transcript variant 2* 2.8 2.05 0.0155 0.0159
Dual specificity phosphatase 6 2.78 0.0066
Chemokine (C-C motif) ligand 6 2.77 2.33 0.0010 0.0304
Interleukin enhancer binding factor 2 2.77 2.94 0.0260 0.0320
Fc receptor, IgG, a chain transporter 2.73 0.0086
Bmi1 polycomb ring finger oncogene 2.72 2.02 0.0253 0.0106
Immunoglobulin heavy chain complex* 2.71 4 0.0248 0.0033
Ectonucleotide pyrophosphatase/phosphodiesterase 2 2.68 0.0037
Immunoglobulin joining chain 2.65 0.0001
Presenilin 1 2.61 0.0069
Complement component 1, s subcomponent, transcript variant 1 2.58 0.0013
2-5 oligoadenylate synthetase-like 2* 2.56 0.0051
Fc receptor, IgE, high affinity I, gamma polypeptide 2.49 0.0037
Guanylate-binding protein 10 2.44 0.0019
SAM and SH3 domain containing 3* 2.42 0.0070
CD79B antigen* 2.39 2.69 0.0154 0.0050
Vav 1 oncogene* 2.39 0.0314
Interferon inducible GTPase 1 2.38 1.58 0.0093 0.0438
Chemokine (C-C motif) receptor 2 2.36 1.61 0.0024 0.0404
Protein kinase RICK 2.36 0.0008
Strain SJL/J small inducible cytokine A4 2.32 0.0032
Interleukin 33 2.31 2.45 0.0006 0.0114
Tumor necrosis factor, a-induced protein 8-like 2 2.31 0.0405
Lymphocyte cytosolic protein 1 2.28 0.0204
Serine (or cysteine) peptidase inhibitor, clade G, member 1 2.28 0.0009
Yamaguchi sarcoma viral (v-yes-1) oncogene homolog 2.28 0.0165
Chemokine (C-X-C motif) ligand 13 2.3 2.38 0.0020 0.0036
Guanylate binding protein 3* 2.27 0.0155
C-type lectin domain family 7, member a 2.24 2.87 0.0015 0.0011
Chemokine (C-X-C motif) ligand 9* 2.22 2.07 0.0260 0.0242
Phospholipid scramblase 1 2.21 0.0070
Glutathione peroxidase 2 2.19 0.0046
Annexin A3 2.18 1.89 0.0202 0.0100
A-synuclein 2.15 0.0012
Guanylate binding protein 4 2.15 0.0072
Killer cell lectin-like receptor family E member 1 2.15 0.0081
Interferon induced with helicase C domain 1 2.15 0.0198
Transporter 1, ATP-binding cassette, sub-family B4 2.13 0.0244
Dual specificity phosphatase 6 2.07 0.0183
Nuclear receptor subfamily 1, group H, member 3 2.07 0.0093
Vitronectin 2.07 0.0457
Toll-like receptor 3 2.06 0.0029
Syntaxin binding protein 2 2.06 0.0229
CD55 antigen 2.04 0.0146
Toll-like receptor 2 2.02 3.51 0.0104 0.0035
High mobility group box 1 2.02 0.0012
Guanylate binding protein 6 2 0.0040
Relative ratios were calculated from CL and Affy data by comparing the degree of gene expression in lacrimal glands from P- versus T-treated
female MRL/lpr mice. Listed CL genes were increased ‡2-fold.
* Genes were found to be upregulated in lacrimal glands of female NOD mice treated with T (Table 8).
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TABLE 8. T-Stimulated Increase of Gene Expression in the Immune Response Ontology in Lacrimal Glands From Female NOD Mice
Gene CL Ratio Affy Ratio CL P Value Affy P Value
Chemokine (C-X-C motif) ligand 10 10.71 4.86 0.0056 0.0183
Forkhead box P3 10.7 0.0007
MHC I¼H-2Kd homolog 10.39 0.0001
Chemokine (C-X-C motif) ligand 9* 10.01 33.35 0.0066 0.0021
Adenosine A2b receptor 9.81 3.87 0.0145 0.0002
Histocompatibility 2, K1, K region 9.71 0.0000
Interferon regulatory factor 7 9.33 4.15 0.0198 0.0002
Interleukin 21 8.12 0.0031
Tripartite motif-containing 25 8.01 0.0205
Chemokine (C-C motif) ligand 5 7.21 15.38 0.0192 0.0103
Histocompatibility 2, blastocyst 7.2 0.0075
Chemokine (C-C motif) ligand 8 7.06 7.68 0.0017 0.0004
Lymphotoxin B 6.63 8.35 0.0115 0.0082
Guanylate binding protein 2* 6.54 6.6 0.0204 0.0029
CD86 antigen 6.37 4.34 0.0035 0.0013
Interferon regulatory factor 8, mRNA
(cDNA clone MGC:6194 IMAGE:3487214)
6.35 5.34 0.0026 0.0068
CD247 antigen 6.19 0.0036
Guanylate-binding protein 10 6.12 0.0279
Complement component 4B 6.05 4.46 0.0054 0.0044
Chemokine (C motif) ligand 1 5.94 0.0247
Transporter 1, ATP-binding cassette, sub-family B 5.84 7.76 0.0009 0.0000
Chemokine (C-C motif) receptor 7 5.75 0.0411
Immunity-related GTPase family M member 1 5.72 5.63 0.0051 0.0074
Myxovirus (influenza virus) resistance 2) 5.72 0.0042
Solute carrier family 11, member 1 5.67 0.0119
Tumor necrosis factor receptor superfamily, member 1b 5.65 0.0007
Interferon regulatory factor 8 5.44 0.0001
Immunity-related GTPase family M member 2 5.14 7.03 0.0091 0.0158
Bone morphogenetic protein 6 5.13 0.0447
Similar to histocompatibility 2, D region locus 1 5.06 3.94 0.0053 0.0238
Cytochrome b-245, a polypeptide 5.03 5.79 0.0211 0.0092
Guanylate binding protein 3* 4.99 4.51 0.0107 0.0010
Chemokine (C-C motif) ligand 7 4.88 0.0158
Cell division cycle 2 homolog A 4.87 0.0282
SAM domain and HD domain, 1 4.81 4.94 0.0045 0.0064
B-2 microglobulin mRNA, segment 1 4.69 0.0012
CD40 antigen (Cd40), transcript variant 5 4.67 0.0064
Lymphocyte protein tyrosine kinase 4.66 5.74 0.0039 0.0250
Fc receptor, IgE, high affinity I, gamma polypeptide 4.58 0.0034
Protein tyrosine phosphatase, receptor type, C, transcript variant 2* 4.54 0.0046
Immunoglobulin heavy chain complex* 4.46 5.27 0.0058 0.0043
SAM and SH3 domain containing 3* 4.45 2.82 0.0123 0.0054
Arrestin, b2 4.44 0.0013
2-5 oligoadenylate synthetase 1B 4.39 0.0160
Fc receptor, IgG, high affinity I 4.38 3.21 0.0300 0.0098
Protein tyrosine phosphatase, nonreceptor type 22 4.38 0.0011
Histocompatibility 2, Q region locus 1 4.35 3.11 0.0145 0.0005
CD79A antigen 4.3 0.0022
Leukocyte specific transcript 1 4.23 0.0426
Lymphocyte antigen 86 4.19 0.0386
2-5 oligoadenylate synthetase-like 2* 4.14 7.25 0.0139 0.0059
Myxovirus resistance 1 4.1 0.0115
Complement component 1, q subcomponent, C chain 4.04 0.0011
CD74 antigen 3.98 4.48 0.0119 0.0003
CD79B antigen* 3.95 0.0497
Toll-like receptor 1 3.95 3.2 0.0138 0.0130
Transforming growth factor, b1 3.9 0.0276
SH2 domain protein 1A 3.87 0.0210
Vav 1 oncogene* 3.84 0.0145
B-2 microglobulin, segment 1 3.79 0.0002
Interferon-inducible GTPase-like 3.79 0.0006
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lacrimal glands of MRL/lpr and NOD mice are identical. Thus,
androgen decreased the expression of multiple immune-related
genes in lacrimal tissues of female MRL/lpr mice, and T
increased the expression of these immune genes, which are
typically expressed in NOD males,30 in female NOD lacrimal
tissues. We also discovered that many of these regulated genes
are the same as those typically highly expressed in inflamed
compared to noninflamed lacrimal glands.
Are there specific genes, then, that might be responsible, at
least in part, for promoting the anomalous androgen-induced
inflammation in NOD lacrimal glands? Possible genes might be
those encoding kallikrein 1 and its related peptidases (KLKs)
b1, b4, b5, b8, b11, b24, and b26. Testosterone increased the
expression of these genes by 8.4- to 216.7-fold amounts in
female NOD lacrimal tissues. KLKs constitute a family of serine
proteases that are stimulated by androgens in other tissues51
and appear to have a significant role in the development and
progression of autoimmune diseases.52,53 KLK protein levels
are increased in lacrimal glands in primary SS.54,55 Further,
several KLKs act as autoantigens, and may serve to elicit an
autoimmune T-cell response against lacrimal tissue and to
cause a decrease in aqueous tear secretion.54,56–58 However, it
is unlikely that KLKs are the keys to understanding androgen-
immune effects in NOD mice. The reason is that T also
increases by 1.7- to 273-fold the gene expression of KLKs b1,
b4, b8, b10, b11, b16, b21, b24, b26, and b27 in lacrimal
glands of female MRL/lpr mice, and by 38.8-fold the KLK b24
gene activity in female nonautoimmune BALB/c mice.31
Another gene that might be responsible for increasing the
aberrant androgen-induced inflammation in NOD lacrimal
glands is Syk. This tyrosine kinase is very much involved in
signaling pathways in hematopoietic cells, and also functions
within epithelial cells to promote inflammatory responses.59,60
Syk inhibition has been proposed as a potential treatment for
SLE and SS.61 However, although Syk gene expression is
increased in the inflamed lacrimal glands of female MRL/lpr
mice (NCBI GEO series accession number GSE5876), it is not
decreased by androgen treatment in this strain. Consequently,
if there is a specific lacrimal gland switch that androgens turn
on to induce immunopathology in NOD mice, and turn off to
suppress inflammation in MRL/lpr mice, then Syk is not that
switch.
What, then, is that possible on/off switch? We hypothesized
that this switch, which may comprise a single or multiple
genes, is triggered by an androgen–androgen receptor interac-
tion within lacrimal gland epithelial cell nuclei. These classical
androgen receptors are members of the nuclear receptor
superfamily of ligand-inducible transcription factors and
TABLE 8. Continued
Gene CL Ratio Affy Ratio CL P Value Affy P Value
Linker for activation of T cells family, member 2* 3.68 0.0308
Interferon induced with helicase C domain 1 3.59 0.0162
Complement component 1, q subcomponent, a polypeptide 3.57 0.0062
Complement component 3a receptor 1 3.57 0.0025
Interleukin 3 3.55 0.0146
Histocompatibility 2, class II antigen A, b1 3.54 3.42 0.0106 0.0243
CD3 antigen, epsilon polypeptide 3.52 0.0171
Interleukin 18 receptor 1 3.52 0.0062
Relative ratios were determined from CL and Affy data by comparing the degree of gene expression in lacrimal glands from P- versus T-treated
female NOD mice. Listed CL genes were increased ‡3.50-fold.
* Genes were found to be down-regulated in lacrimal glands of female MRL/lpr mice treated with T (Table 7).
TABLE 9. Inflammatory Gene Responses That Were Similar in Lacrimal Glands From Female MRL/lpr and NOD Mice
Gene MRL/lpr Ratio NOD Ratio MRL/lpr P Value NOD P Value
Downregulation
Indoleamine 2,3-dioxygenase 1 4.55 3.65 0.0073 0.0172
UDP-Gal:bGlcNAc b 1,4-galactosyltransferase, polypeptide 1 4.52 12.98 0.0006 0.0009
Interleukin 33 2.31 1.84 0.0006 0.0352
Tachykinin 1 2.17 2.54 0.0236 0.0010
Purinergic receptor P2X, ligand-gated ion channel 1.63 1.78 0.0325 0.0255
Adiponectin, C1Q and collagen domain containing 1.46 3.58 0.0101 0.0046
Junction adhesion molecule 3 1.4 1.77 0.0068 0.0136
Upregulation
TLR4 interactor with leucine rich repeats 30.47 7.29 0.0277 0.0011
Adenosine A2b receptor 22.87 9.81 0.0053 0.0145
Paraneoplastic antigen MA1 16.63 2.91 0.0001 0.0181
Carbohydrate sulfotransferase 2 15.49 2.13 0.0012 0.0130
Forkhead box P3 11.51 10.7 0.0036 0.0007
Nucleotide-binding oligomerization domain containing 2 10.82 2.65 0.0134 0.0004
Toll-like receptor 9 3.45 1.67 0.0125 0.0170
Chemokine (C-C motif) receptor 5 2.25 2.05 0.0045 0.0078
V-rel reticuloendotheliosis viral oncogene homolog A 1.66 3.06 0.0091 0.0033
Transforming growth factor, b1 1.47 3.9 0.0043 0.0276
Regenerating islet-derived 3a 1.42 1.43 0.0207 0.0222
Relative ratios were calculated from CL data by comparing the degree to which gene expression was significantly down- or upregulated by T
treatment, relative to that of P, in lacrimal glands of female MRL/lpr and NOD mice.
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mediate the majority of androgen actions throughout the
body.62,63 Following androgen association with its specific
receptor, the monomeric, activated androgen-receptor com-
plex binds to androgen response elements in the regulatory
region of target genes and, in combination with coactivators
and enhancers, regulates gene transcription, and ultimately
protein synthesis and tissue function.62–67
We have shown that androgen receptors are located almost
exclusively within acinar and ductal epithelial cell nuclei in
lacrimal glands of MRL/lpr mice, and are absent within the
extensive lymphocytic populations in these autoimmune
tissues.68 Moreover, we have found that androgens upregulate
the expression of androgen receptor protein in MLR/lpr
lacrimal gland epithelia, and this autoregulation is particularly
intense in ductal epithelial cells.68 Indeed, the highest level of
androgen receptor protein in ductal nuclei68 is elicited by
those androgens that possess the greatest anti-inflammatory
activity in MRL/lpr lacrimal tissue.14 Given the role of the
periductal area in promoting inflammation within the lacrimal
gland,69 it may be that an androgen-controlled on/off switch
exists in ductal epithelial cells. Epithelial cells, in turn, are
thought to be the primary cells involved in the initiation and
perpetuation of glandular autoimmune reactivity in Sjo¨gren
syndrome.70,71
Consistent with a regulatory role for ductal epithelial cells is
the finding that infiltration of lacrimal glands in AIRE-deficient
NOD mice appears to localize to ductal tissue.72 AIRE is a
transcription factor and autoimmune regulator that enforces
self-tolerance; humans expressing a defective form of this gene
develop multiorgan autoimmune disease.73 Interestingly, cor-
rection of ductal epithelial function also has been shown to
correct acinar epithelial function.74 This domino effect
suggests that ductal cells have an essential role in the
pathogenesis of lacrimal gland dysfunction and ultimately
aqueous tear film deficiency
Why then is there an aberrant androgen immune response
in lacrimal glands of NOD mice? Could this response be related
to a genetic alteration in the androgen receptor, or to changes
in the hypothalamic-pituitary-adrenal (HPA) axis, or to the
diabetes that is characteristic of this strain? Defects in sex
steroid receptors have been linked to the onset, progression,
and severity, as well as the sex-related prevalence, of a number
of autoimmune disorders, including lupus, rheumatoid arthri-
tis, and diabetes.75 These defects often are due to gene
polymorphisms or alternative splicing and may lead to marked
changes in the affinity or specificity of ligand binding, nuclear
translocation, receptor dimerization, DNA association, and
transcriptional activation.75 However, we found that the
coding region of androgen receptors in lacrimal glands of
NOD and MRL/lpr mice is not defective, but rather normal.75
As concerns the HPA axis, we previously discovered that
hypophysectomy or anterior pituitary ablation significantly
interferes with androgen action on the lacrimal gland.76 This
lacrimal gland impairment appears to be tissue-specific.77
However, although the pituitary has blunted responses in
humans with SS,78 NOD mice have a hyperactive HPA79 and
this would not inhibit androgen effects on lacrimal tissue. With
regard to diabetes, insulin deficiency is known to attenuate the
lacrimal gland response to androgen,80 but there is no
evidence that this condition would promote a completely
TABLE 10. Immune KEGG Pathways Downregulated in Lacrimal Glands by T Administration to Female MRL/lpr Mice
KEGG Pathway CL Genes  Affy Genes  CL z-Score Affy z-Score
Chemokine signaling pathway 28 2.92
Cytokine-cytokine receptor interaction 36 2.79
Toll-like receptor signaling pathway 17 2.47
B cell receptor signaling pathway 14 2.4
Leukocyte transendothelial migration 17 19 2.05 2.06
Phagosome 22 2.01
Immune-related KEGG pathways that were decreased in T-, as compared to P-, treated female MRL/lpr mice are listed.
TABLE 11. T Upregulation of Immune KEGG Pathways in Lacrimal Glands of Female NOD Mice
KEGG Pathway CL Genes  Affy Genes  CL z-Score Affy z-Score
Natural killer cell mediated cytotoxicity 38 17 8.37 2.47
Graft-versus-host disease 18 12 7.96 4.99
Allograft rejection 17 10 7.41 3.94
Antigen processing and presentation 23 16 7.11 4.83
Leishmaniasis 24 7.03
Autoimmune thyroid disease 17 10 6.4 2.99
Toll-like receptor signaling pathway 26 16 5.71 3.07
Primary immunodeficiency 13 9 5.46 3.87
Phagosome 32 28 4.97 4.85
Cytokine-cytokine receptor interaction 44 4.78
Chemokine signaling pathway 34 26 4.67 3.52
T-cell receptor signaling pathway 24 4.54
Systemic lupus erythematosus 17 14 4.25 3.23
B-cell receptor signaling pathway 18 12 4.21 2.77
Jak-STAT signaling pathway 26 3.66
Intestinal immune network for IgA production 10 3.31
Fc gamma R-mediated phagocytosis 16 14 2.77 2.85
Complement and coagulation cascades 14 2.76
Leukocyte transendothelial migration 17 17 2.17 2.8
Immune-related KEGG pathways that were increased in T-, as compared to P-, treated female NOD mice are listed.
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TABLE 12. Sex and T Influence on Immune-Related Gene Ontologies in Lacrimal Glands of Autoimmune Mice
Gene Ontology
lpr lpr lpr lpr NOD NOD NOD NOD lpr þNOD lpr þNOD
F  F  z T  T  z M  M  z T  T  z Infl  Infl  z
Immune system process 228 6.26 166 7.27 227 14.62 192 13.29 238 18.47
Immune response 133 5.89 90 5.45 152 15.16 127 13.54 161 18.74
Defense response 141 6.12 89 4.73 134 11.7 115 10.91 139 14.42
Regulation of immune system process 119 4.29 79 3.9 128 11.66 111 11.05 130 13.88
Leukocyte activation 100 5.51 65 4.58 99 10.89 87 10.52 112 15.01
Positive regulation of immune system process 85 3.99 55 3.33 102 12.13 86 10.98 103 14.06
Lymphocyte activation 84 4.84 55 4.11 83 9.72 72 9.2 97 14.08
Regulation of immune response 77 4.38 43 2.31 90 11.75 77 10.88 89 13.18
Immune effector process 74 5.38 39 2.56 81 11.65 71 11.16 84 13.89
Innate immune response 56 3.15 46 4.75 69 10.11 62 10.06 74 12.72
Positive regulation of immune response 59 3.72 37 2.82 75 11.48 62 10.1 74 12.76
T-cell activation 55 3.53 38 3.46 60 8.74 53 8.5 67 11.75
Cytokine production 72 5.12 41 3.03 63 7.94 59 8.52 66 9.93
Regulation of leukocyte activation 56 4.11 34 2.87 58 8.71 54 9.16 62 11
Regulation of lymphocyte activation 51 4.12 32 3.13 54 8.81 48 8.63 60 11.65
Inflammatory response 71 4.8 39 2.51 58 6.75 51 6.57 58 7.99
Regulation of cytokine production 62 4.65 33 2.23 54 7.21 51 7.85 58 9.39
Regulation of defense response 60 3.79 41 3.6 55 6.95 49 6.9 56 8.4
Leukocyte proliferation 47 4.96 31 4.19 43 7.72 38 7.5 55 12.35
Lymphocyte proliferation 46 4.95 30 4.08 43 7.93 37 7.41 55 12.62
Activation of immune response 41 2.52 30 2.98 55 9.56 44 8.01 54 10.58
Response to cytokine stimulus 49 3.34 47 6.4 45 6.21 39 5.89 48 8.08
Positive regulation of defense response 39 3.14 29 3.61 37 6.02 32 5.68 37 7.03
The number of genes (i.e., non–z-score columns) and z-scores (z) were obtained by analyzing comparative CL microarray data from lacrimal
glands from female (F) versus male (M) and P-versus T-treated MRL/lpr (lpr) and NOD mice. The sex-related data originate from one of our recent
publications.30 The last two columns on the right show results obtained by comparing gene expression in inflamed (Infl) versus noninflamed
lacrimal tissues, as described in the Results section. Ontologies were significantly (P < 0.05) up ()- or down ()-regulated according to the listed sex
and hormone treatment.
TABLE 13. Sex and T Effect on the Expression of Immune Response Genes in Lacrimal Glands of Autoimmune Mice
Gene Ontology
lpr lpr lpr lpr NOD NOD NOD NOD lpr þNOD lpr þNOD
F  F  P T  T  P M  M  P T  T  P Infl  Infl  P
Chemokine (C-X-C motif) ligand 9 4.21 0.0053 2.22 0.0260 15.74 0.0000 10.01 0.0066 5.56 0.0000
CD79B antigen 3.56 0.0001 2.39 0.0154 11.31 0.0002 3.95 0.0497 5.49 0.0018
SAM and SH3 domain containing 3 3.34 0.0019 2.42 0.0070 6.26 0.0001 4.45 0.0123 4.03 0.0000
Linker for activation of T cells family, member 2 2.48 0.0136 4.09 0.0024 6.04 0.0005 3.68 0.0308 3.93 0.0000
Vav 1 oncogene 2.78 0.0008 2.39 0.0314 5.52 0.0000 3.84 0.0145 3.48 0.0000
Complement component 3 4.38 0.0050 2.94 0.0015 3.14 0.0050 3.15 0.0109 3.44 0.0000
C-type lectin domain family 7, member a 3.11 0.0025 2.24 0.0015 5.45 0.0024 2.99 0.0177 3.29 0.0000
Immunoglobulin heavy chain complex 5.47 0.0014 2.71 0.0248 8.51 0.0028 4.46 0.0058 3.2 0.0000
Complement component 4B 1.52 0.0361 1.98 0.0147 5.38 0.0053 6.05 0.0054 3.12 0.0000
interleukin 4 receptor, a 4.35 0.0039 1.73 0.0241 3.91 0.0025 2.68 0.0279 3.06 0.0015
Chemokine (C-X-C motif) ligand 16 6.95 0.0116 3.01 0.0003 1.75 0.0142 2.86 0.0175 2.93 0.0000
Histocompatibility 2, class II antigen A, a 2.64 0.0142 1.69 0.0065 4.22 0.0017 3.13 0.0064 2.87 0.0000
Toll-like receptor 1 2.34 0.0083 1.45 0.0456 4.28 0.0094 3.95 0.0138 2.79 0.0000
Histocompatibility 2, class II antigen E b 2.3 0.0429 1.59 0.0439 4.87 0.0001 3.18 0.0151 2.77 0.0000
Toll-like receptor 2 3.31 0.0033 2.02 0.0104 3.04 0.0003 2.65 0.0111 2.71 0.0000
Immunity-related GTPase family M member 2 2.25 0.0229 1.94 0.0132 3.79 0.0005 5.14 0.0091 2.69 0.0000
Chemokine (C-C motif) receptor 2 2.31 0.0063 2.36 0.0024 3.38 0.0028 2.45 0.0050 2.63 0.0000
Phospholipid scramblase 1 3.54 0.0323 2.21 0.0070 2.01 0.0002 2.4 0.0140 2.5 0.0001
Purinergic receptor P2Y, G-protein coupled, 14 2.32 0.0114 1.34 0.0460 3.69 0.0028 3.15 0.0074 2.47 0.0000
Transmembrane protein 173 4.54 0.0033 1.31 0.0113 3.07 0.0007 1.85 0.0383 2.34 0.0000
Complement component 1, s subcomponent 3.55 0.0039 2.58 0.0013 1.73 0.0096 1.4 0.0133 2.18 0.0002
Interleukin 1b 1.64 0.0146 1.57 0.0329 2.72 0.0001 1.69 0.0456 1.89 0.0001
Relative ratios and P values were calculated from CL data by comparing the degree of gene expression in lacrimal glands from female versus
male, P- versus T-treated, and inflamed versus noninflamed MRL/lpr and NOD mice. The categories, abbreviations, and origin of the sex-related data
are described in the legend to Table 11.
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opposite immune response to androgens as found in NOD
compared to MRL/lpr mice.
As one additional consideration, it has been proposed that a
defect in male-specific, lacrimal gland-protective T regulatory
cells is the cause of the lacrimal gland inflammation in NOD
mice, and is driven by a T regulatory cell-extrinsic factor.81
However, given that we were able to induce a striking increase
in inflammatory gene expression in lacrimal tissue of NOD
female mice, it would seem that androgen action has the key
role in this T-cell effector/regulator imbalance.
The androgen-induced up- and downregulation of inflam-
matory gene expression in NOD and MRL/lpr mice, respec-
tively, appears to be mediated through the lacrimal gland
environment. Consistent with this hypothesis are the results
of adoptive transfer experiments in NOD mice with severe
combined immune deficiency (SCID). These animals lack
functional T and B cells and do not suffer autoimmune
disease. Transfer of splenocytes or cervical lymph node cells
from a female NOD mouse to a male NOD.SCID causes
massive inflammatory lesions in the lacrimal gland, whereas
transfer of male NOD splenocytes or cervical lymph node
cells to a female NOD.SCID does not elicit such lacrimal tissue
infiltration.24,81 Further, the lacrimal gland inflammatory
response can be reduced by castration of a male NOD
mouse,23 and induced by androgen treatment of a female
NOD mouse (this study).
It is possible that intracrine steroidogenic enzymes convert
androgens in the NOD lacrimal gland into metabolites that act
through different mechanisms than testosterone, such as may
occur in the brain.82 Such byproducts could have aberrant
forms, given that unusual androgen metabolites are the key
serum biomarkers for dry eye disease.83 Alternatively, it is
possible that epithelial cells in NOD lacrimal tissue, like human
prostate epithelial cells, demonstrate significant plasticity in
response to androgens.84 Nevertheless, the identity of the
microenvironmental switch(es) that translate androgen action
into an up- or downregulation of immune-related gene
expression in the lacrimal gland remains to be discovered.
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